|
US2021079014A1
|
|
Functionalized heterocycles as antiviral agents
|
|
WO2021066922A1
|
|
Antiviral heterocyclic compounds
|
|
WO2021007488A1
|
|
Substituted heterocycles as antiviral agents
|
|
US2020385391A1
|
|
Hepatitis b antiviral agents
|
|
WO2020247561A1
|
|
Hepatitis b antiviral agents
|
|
WO2020247444A1
|
|
Hepatitis b antiviral agents
|
|
US2020361920A1
|
|
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US2020323872A1
|
|
Heterocyclic compounds as rsv inhibitors
|
|
US2020308193A1
|
|
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
|
|
US2020299286A1
|
|
Benzodiazepine derivatives as rsv inhibitors
|
|
US2020165249A1
|
|
Functionalized heterocycles as antiviral agents
|
|
WO2020106707A1
|
|
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
|
|
CA3113235A1
|
|
Functionalized heterocycles as antiviral agents
|
|
WO2020041417A1
|
|
Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
|
|
CA3052361A1
|
|
Process for the preparation of benzodiazepine derivatives
|
|
US2019337935A1
|
|
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
|
|
AU2019262016A1
|
|
Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
|
|
WO2019199908A1
|
|
Heterocyclic compounds as rsv inhibitors
|
|
US2019321360A1
|
|
Hepatitis B antiviral agents
|
|
WO2019160813A1
|
|
Isoxazole derivatives as fxr agonists and methods of use thereof
|
